Search

5 results

Reset

UpdatesJan 19, 2026

Beyond kin killing: Dickeya-derived phage-tail-like bacteriocin P2D1 targets phylogenetically distant Pseudomonas spp.

P2D1 tailocin from Dickeya dadantii was active against nine Pseudomonas strains among 480 soil and rhizosphere isolates. Six susceptible, nonpathogenic strains mitigated Dickeya-induced soft rot on potato; three related P. tensinigenes isol

Updates Papers Tailocins Pseudomonas
Therapy studies

Ph 1/2 Study Evaluating Safety and Tolerability of Inhaled AP-PA02 in Subjects With Chronic Pseudomonas Aeruginosa Lung Infections and Cystic Fibrosis

Completed. Checked 2026-10-03. Phase 1b/2a, double-blind, randomized, placebo-controlled, single and multiple ascending dose study to evaluate the safety, tolerability and phage recovery profile of AP-PA02 multi-bacteriophage therapeutic ca

phage bacteriophage cystic fibrosis Pseudomonas Pseudomonas aeruginosa
Therapy studies

Personalized Phage Treatment in Covid-19 Patients With Bacterial Co-Infections Microbials for Pneumonia or Bacteremia/Septicemia

Unavailable. Checked 2026-10-03. Phage Treatment in Covid-19 Patients with Bacterial Co-Infections Expanded Access Study of Phage Treatment in Covid-19 Patients on Anti-Microbials for Pneumonia or Bacteremia/Septicemia Due to A. Baumannii,

Covid19 Bacteriophage Phage Bacteremia Septicemia Acinetobacter baumannii Pseudomonas Aeruginosa Infection Staph Aureus
Therapy studies

CYstic Fibrosis bacterioPHage Study at Yale (CYPHY)

Completed. Checked 2026-10-03. This is a Phase 2 study with primary objective of looking whether YPT-01 phage therapy reduces sputum bacterial load in cystic fibrosis subjects with Pseudomonas aeruginosa. In addition, study evaluates the s

Pseudomonas bacteriophage phage
Therapy studies

Study to Evaluate the Safety, Phage Kinetics, and Efficacy of Inhaled AP-PA02 in Subjects With Non-Cystic Fibrosis Bronchiectasis and Chronic Pulmonary Pseudomonas Aeruginosa Infection

Completed. Checked 2026-10-03. A phase 2, multi-center, double-blind, randomized, placebo-controlled study to evaluate the safety, phage kinetics, and efficacy of inhaled AP-PA02 administered in subjects with non-cystic fibrosis bronchiecta

Bacteriophage Phage NCFB BE Pseudomonas Pseudomonas Aeruginosa